Boston Scientific (BSX) said Monday it agreed to acquire medical device company SoniVie.
Boston Scientific currently owns an equity stake of around 10 percent in SoniVie. The transaction consists of an upfront payment of $360 million for the remaining 90% stake and up to $180 million upon achievement of a regulatory milestone.
SoniVie's main product is the Tivus intravascular ultrasound system, an investigational technology designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension. The Tivus system is designed to help reduce activity in the kidney's renal nerves and serve as an alternative or adjunctive therapy to medications to help regulate blood pressure.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。